File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600000000612

Vectormune FP ILT + AE (--) Lyophilisate and solvent for suspension for injection

Authorised

- Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live
- Avian encephalomyelitis virus, strain Calnek 1143, Live

Product identification

Medicine name:
Vectormune FP ILT + AE (--) Lyophilisate and solvent for suspension for injection

Active substance:
Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live

Avian encephalomyelitis virus, strain Calnek 1143, Live

Target species:
Chicken

Route of administration:
Wing-web-stab use

Product details

Active substance and strength:

Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live

Presentation_strength:2.7 to 4.5 log_{10} $TCID_{50}$ Reference:HSE Index:0

Avian encephalomyelitis virus, strain Calnek 1143, Live

Presentation_strength:2.7 to 4.5 log_{10} EID_{50} Reference:HSE Index:1

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:

Wing-web-stab use:

- **Chicken**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Bulgaria , Cyprus , Czechia , Denmark , France , Germany , Greece , Hungary , Italy , Latvia , Luxembourg , Netherlands , Poland , Portugal , Romania , Slovakia , Slovenia , Spain

---

Package description:
Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials; solvent: 5 vials; 5 pronged applicators, Content:Lyophilisate: 2000 doses; solvent: 20 ml
Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial; solvent: 1 vial; 1 pronged applicator, Content:Lyophilisate: 1000 doses; solvent: 10 ml
Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials; solvent: 5 vials; 5 pronged applicators, Content:Lyophilisate: 1000 doses; solvent: 10 ml
Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 10 vials; solvent: 10 vials; 10 pronged applicators, Content:Lyophilisate: 1000 doses; solvent: 10 ml
Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 10 vials; solvent: 10 vials; 10 pronged applicators, Content:Lyophilisate: 2000 doses; solvent: 20 ml
Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial; solvent: 1 vial; 1 pronged applicator, Content:Lyophilisate: 2000 doses; solvent: 20 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Ceva-Phylaxia Zrt.

Marketing authorisation date:
24/04/2020

Manufacturing sites for batch release:
Ceva-Phylaxia Zrt.

Responsible authority:

European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
24/04/2020

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 14/03/2026
Download

ema-puar-vectormune-fp-ilt-ae-v-5077-par-en.pdf